These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R; Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606 [TBL] [Abstract][Full Text] [Related]
5. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia]. Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ; Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080 [TBL] [Abstract][Full Text] [Related]
6. Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review. Ruan Q; D'Onofrio G; Sancarlo D; Bao Z; Greco A; Yu Z BMC Geriatr; 2016 May; 16():104. PubMed ID: 27184250 [TBL] [Abstract][Full Text] [Related]
7. Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis. Parnetti L; Chipi E; Salvadori N; D'Andrea K; Eusebi P Alzheimers Res Ther; 2019 Jan; 11(1):7. PubMed ID: 30646955 [TBL] [Abstract][Full Text] [Related]
8. [Evolution of the diagnostic frontiers of Alzheimer's disease and new therapeutic possibilities]. Gavrilova SI Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(11. Vyp. 2):38-44. PubMed ID: 36412155 [TBL] [Abstract][Full Text] [Related]
14. Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease. Assunção SS; Sperling RA; Ritchie C; Kerwin DR; Aisen PS; Lansdall C; Atri A; Cummings J Alzheimers Res Ther; 2022 Apr; 14(1):54. PubMed ID: 35440022 [TBL] [Abstract][Full Text] [Related]
15. Biomarkers for preclinical Alzheimer's disease. Tan CC; Yu JT; Tan L J Alzheimers Dis; 2014; 42(4):1051-69. PubMed ID: 25024325 [TBL] [Abstract][Full Text] [Related]
16. Souvenaid for Alzheimer's disease. Burckhardt M; Watzke S; Wienke A; Langer G; Fink A Cochrane Database Syst Rev; 2020 Dec; 12(12):CD011679. PubMed ID: 33320335 [TBL] [Abstract][Full Text] [Related]
17. When Does Alzheimer's Disease Really Start? The Role of Biomarkers. Lloret A; Esteve D; Lloret MA; Cervera-Ferri A; Lopez B; Nepomuceno M; Monllor P Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31698826 [TBL] [Abstract][Full Text] [Related]
18. The Trajectory of Cerebrospinal Fluid Growth-Associated Protein 43 in the Alzheimer's Disease Continuum: A Longitudinal Study. Zhang H; Lyu D; Jia J; J Alzheimers Dis; 2022; 85(4):1441-1452. PubMed ID: 34958042 [TBL] [Abstract][Full Text] [Related]
19. Rethinking on the concept of biomarkers in preclinical Alzheimer's disease. Berti V; Polito C; Lombardi G; Ferrari C; Sorbi S; Pupi A Neurol Sci; 2016 May; 37(5):663-72. PubMed ID: 26792010 [TBL] [Abstract][Full Text] [Related]
20. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL; Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]